Elliot Norry Receives Stock Award at Adaptimmune Therapeutics Plc (ADAP) — SEC Form 4, Jan 17, 2023

SEC Form 4 · No Market Transaction
Stock Award

Compensation grant — no market purchase or sale.

Reporting Owner
Elliot Norry
Officer
TXN 2023-01-17 · FILED 2023-01-17
Filing Lag 0 business days within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership

Adaptimmune Therapeutics Plc

ADAP CIK 0001621227
All Adaptimmune Therapeutics Plc insider activity
Filing Date
2023-01-17
Report Date
2023-01-17
Accession No.
0001104659-23-004371
Accepted At
2023-01-18 02:03 UTC
Reporting Owner
Name Relationship
Elliot Norry CIK 0001798117
Officer
Elliot Norry at Adaptimmune Therapeutics Plc Full insider history
Bought (12 mo) —
Sold (12 mo) —
More from this insider at Adaptimmune Therapeutics Plc
2025-02-20 Award — View
2025-01-17 Sell -$3,243 View
2025-01-15 Sell -$12,920 View
2024-01-17 Sell -$14,106 View
2024-01-17 Award — View
All filings by this insider at Adaptimmune Therapeutics Plc
Derivative Securities Transactions
Title Strike Date Type Shares Price Expiration Underlying Ownership
Option to purchase Ordinary SharesF1F2 $0.31 2023-01-17 A - Award/Grant 1,407,072 A $0.00 2033-01-17 1,407,072 Ordinary Shares Direct
Option to purchase Ordinary SharesF3F4F5 $0.00 2023-01-17 A - Award/Grant 314,256 A $0.00 314,256 Ordinary Shares Direct
Option to purchase Ordinary SharesF6 $0.00 2023-01-17 A - Award/Grant 193,344 A $0.00 2025-03-15 193,344 Ordinary Shares Direct
Footnotes (6)
F1
The exercise price was converted from GBP0.26 based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount. Show more
F2
Exercisable as to 351,768 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the seventeenth of each month from February 17, 2024 through December 17, 2026 and 29,454 Ordinary Shares on January 17, 2027. Show more
F3
The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount. Show more
F4
Exercisable as to 78,564 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on the seventeenth of each January from January 17, 2025 through January 17, 2027. Show more
F5
The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable. Show more
F6
The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount. Show more

Related filings at Adaptimmune Therapeutics Plc

5%+ Holders · 13D/G 1 filer

Latest Schedule 13D/G per filer; stakes the filer reported closed are left out.

Other insiders at Adaptimmune Therapeutics Plc
All Adaptimmune Therapeutics Plc insider activity
GET /v1/forms/4/0001104659-23-004371 API docs
View Original SEC Filing